STRUBLE K, MURRAY J, SCHNEIDER B, SOON G; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. I-1329.
Food and Drug Administration, Rockville, MD
BACKGROUND: Recent reports have suggested that HIV + patients receiving PI regimens may develop osteopenia and osteoporosis at higher rates than HIV - controls or HIV + patients receiving no treatment or non- PI regimens. However, the clinical significance of the reported loss of bone mineral in HIV + patients is unknown. Therefore, we attempted to determine clinical FX rates in patients receiving PI and non-PI regimens. METHODS: We retrospectively analyzed 13 trials that enrolled PI-naive patients with an approximate mean follow up of 48 weeks. All of the approved antiretroviral agents were represented in this sample. Data collected included: # patients with clinical FXs in each tx group; time to fracture; CD4, RNA and weight at baseline and at time of FX; steroid use; and other risk factors. Additional analyses will be presented. RESULTS: [table: see text] CONCLUSIONS: There was no significant difference in the proportion of patients with FXs for PI vs Non PI regimens (p=0.17). The mean time to FX event was 311 days. Longer-term data are needed to determine if differences are noted with prolonged use of PI or Non PI-containing regimens.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Anti-Retroviral Agents
- Clinical Protocols
- Fractures, Bone
- HIV Infections
- HIV Protease Inhibitors
- HIV Seropositivity
- Humans
- Reverse Transcriptase Inhibitors
- Risk Factors
Other ID:
UI: 102269358
From Meeting Abstracts